An interventional study of Remimazolam in Endoscopy, Gastrointestinal, sponsored by Tongji Hospital. Completed at 1 site in China. Open to participants aged 1 Year to 12 Years. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment
Exploring the effect of remimazolam dose on paradoxical reactions in pediatric painless gastrointestinal endoscopy.
Exploring the effect of remimazolam dose on paradoxical reactions and sedation in pediatric painless gastrointestinal endoscopy, observing the performance and duration of paradoxical reactions, and analyze the factors.
Tongji Hospital is the lead sponsor of 373 studies on the registry; 204 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The first induction dose of remimazolam is 0.1mg/kg.
Drug: Remimazolam
The first induction dose of remimazolam is 0.2mg/kg.
Drug: Remimazolam
The first induction dose of remimazolam is 0.3mg/kg.
Drug: Remimazolam
Observe the incidence of paradoxical reactions after the first induction.
Also known as: remimazolam besylate
incidence of paradoxical reaction
observe the incidence of paradoxical reaction within 2 minutes
Time frame: 2 minutes after first infusion of remimazolam
performance and duration of paradoxical reaction
observe the performance and duration of paradoxical reaction within 2 minutes
Time frame: 2 minutes after first infusion of remimazolam
dosage of sedative drugs
Total dose of the first administered plus supplemental doses of sedative drugs.
Time frame: First infusion until end of remimazolam administration
time records
anesthesia time, induction time, surgical time, awakening time, and recovery time
Time frame: 1 day
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
respiratory suppression incidence;intraoperative blood pressure and heart rate changes: record the patient's intraoperative blood pressure, heart rate, and the use of related vasoactive drugs; postoperative adverse reactions: such as hypertension, hypotension, tachycardia, gastrointestinal symptoms, postoperative restlessness, etc.
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tongji Hospital